Literature DB >> 11243312

Laragh's lessons in pathophysiology and clinical pearls for treating hypertension.

J Laragh1.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11243312     DOI： 10.1016/s0895-7061(00)01317-0

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN： 0895-7061            Impact factor:   2.689


× No keyword cloud information.
  12 in total

1.  A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.

Authors:  Heather L McArthur; Hope Rugo; Benjamin Nulsen; Laura Hawks; Jill Grothusen; Michelle Melisko; Mark Moasser; Matthew Paulson; Tiffany Traina; Sujata Patil; Qin Zhou; Richard Steingart; Chau Dang; Monica Morrow; Peter Cordeiro; Monica Fornier; John Park; Andrew Seidman; Diana Lake; Theresa Gilewski; Maria Theodoulou; Shanu Modi; Gabriella D'Andrea; Nancy Sklarin; Mark Robson; Mary Ellen Moynahan; Steven Sugarman; Jane E Sealey; John H Laragh; Carmen Merali; Larry Norton; Clifford A Hudis; Maura N Dickler
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

Review 2.  Evaluation of hypertension in children.

Authors:  Gaurav Kapur; Rossana Baracco
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

3.  Tumor Necrosis Factor α Receptor Type 1 Activation in the Hypothalamic Paraventricular Nucleus Contributes to Glutamate Signaling and Angiotensin II-Dependent Hypertension.

Authors:  Clara Woods; Jose Marques-Lopes; Natalina H Contoreggi; Teresa A Milner; Virginia M Pickel; Gang Wang; Michael J Glass
Journal:  J Neurosci       Date:  2020-12-10       Impact factor: 6.167

Review 4.  Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?

Authors:  J C Yugar-Toledo; V Brunelli; J F Vilela-Martin; A Fattori; H Moreno
Journal:  Curr Hypertens Rep       Date:  2018-03-27       Impact factor: 5.369

5.  Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Šárka Jíchová; Libor Kopkan; Zuzana Husková; Šárka Doleželová; Jan Neckář; Petr Kujal; Zdenka Vernerová; Herbert J Kramer; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Rami N Reddy; John R Falck; John D Imig; Luděk Červenka
Journal:  J Hypertens       Date:  2016-10       Impact factor: 4.844

6.  Prediction of primary vs secondary hypertension in children.

Authors:  Rossana Baracco; Gaurav Kapur; Tej Mattoo; Amrish Jain; Rudolph Valentini; Maheen Ahmed; Ronald Thomas
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-12       Impact factor: 3.738

7.  Clinical utility of valsartan in the treatment of hypertension in children and adolescents.

Authors:  Rossana Baracco; Gaurav Kapur
Journal:  Patient Prefer Adherence       Date:  2011-03-17       Impact factor: 2.711

8.  Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.

Authors:  Mai Mehanna; Zhiying Wang; Yan Gong; Caitrin W McDonough; Amber L Beitelshees; John G Gums; Arlene B Chapman; Gary L Schwartz; Kent R Bailey; Julie A Johnson; Stephen T Turner; Rhonda M Cooper-DeHoff
Journal:  Am J Hypertens       Date:  2019-06-11       Impact factor: 3.080

9.  Effects of aqueous extract of Hibiscus sabdariffa on the renin-angiotensin-aldosterone system of Nigerians with mild to moderate essential hypertension: A comparative study with lisinopril.

Authors:  Daniel Chukwu Nwachukwu; Eddy Ikemefuna Aneke; Leonard Fidelis Obika; Nkiru Zuada Nwachukwu
Journal:  Indian J Pharmacol       Date:  2015 Sep-Oct       Impact factor: 1.200

Review 10.  Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis.

Authors:  Yen-Chung Lin; Jheng-Wei Lin; Mai-Szu Wu; Kuan-Chou Chen; Chiung-Chi Peng; Yi-No Kang
Journal:  PLoS One       Date:  2017-12-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.